Erratum: Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline (J Clin Endo Metab (2014) 96: 6 (1915-1942) DOI: 10.1210/jc.2014-1498);Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 6, 2014, Pages 1915-1942

  Lenders, Jacques W M ^a   Duh, Quan Yang ^b   Eisenhofer, Graeme ^c   Gimenez Roqueplo, Anne Paule ^d,e   Grebe, Stefan K G ^f   Murad, Mohammad Hassan ^f   Naruse, Mitsuhide ^g   Pacak, Karel ^h   Young, William F ^f  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f MAYO CLINIC   (United States)

^g NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CORTICOSTEROID; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOXAZOSIN; FLUORODEOXYGLUCOSE F 18; LABETALOL; LEVODOPA; MESALAZINE; METADRENALIN; METHYLDOPA; METIROSINE; MONOAMINE OXIDASE INHIBITOR; NIFEDIPINE; PARACETAMOL; PHENOXYBENZAMINE; PROPRANOLOL; SALAZOSULFAPYRIDINE; SOTALOL; SUCCINATE DEHYDROGENASE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADRENAL SCINTISCANNING; ADRENALECTOMY; BLOOD ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; EVIDENCE BASED PRACTICE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE; GENE MUTATION; GENETIC SCREENING; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOTENSION; LAPAROSCOPIC SURGERY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PARAGANGLIOMA; PERSONALIZED MEDICINE; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; SDHB GENE; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; URINALYSIS;

ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; COMBINED MODALITY THERAPY; CONSENSUS; DIAGNOSTIC IMAGING; DIAGNOSTIC TECHNIQUES, ENDOCRINE; ENDOCRINOLOGY; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; PARAGANGLIOMA; PERIOPERATIVE CARE; PHEOCHROMOCYTOMA;

EID: 84902310939     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/clinem/dgad064     Document Type: Erratum

References (265)

1. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
2. Swiglo BA, Murad MH, Schünemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, an d evaluation system. J Clin Endocrinol Metab. 2008;93:666-673.
3. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and Genetics of Tumours of Endocrine Organs (IARC WHO Classification of Tumours). Lyon, France: World Health Organization; 2004.
4. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665-675.
5. Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med. 1987;147:1289-1293.
6. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12:609-615.
7. Ariton M, Juan CS, AvRuskin TW. Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital. Endocr Pract. 2000;6:249-252.
8. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of second ary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27:193-202.
9. Platts JK, Drew PJ, Harvey JN. Death from phaeochromocytoma: lessons from a post-mortem survey. J R Coll Physicians Lond. 1995;29:299-306.
10. Lo CY, Lam KY, Wat MS, Lam KS. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am J Surg. 2000;179: 212-215.
11. McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med. 2000;3 0: 648-652.
12. Wyszynska T, Cichocka E, Wieteska-Klimczak A, Jobs K, Januszewicz P.Asingle pediatric center experience with 1025 children with hypertension. Acta Paediatr. 1992;81:244-246 .
13. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85: 637-644.
14. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004;25:309-340.
15. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002; 346:1459-1466.
16. Gimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res. 2012;44:328-333.
17. Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab. 2001;86:1480-1486.
18. Khorram-Manesh A, Ahlman H, Nilsson O, Odén A, Jansson S. Mortality associated with pheochromocytoma in a large Swedish cohort. Eur J Surg Oncol. 2004;30:556-559.
19. Prejbisz A, Lende rs JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. J Hypertens. 2011; 29:2049-2060.
20. Zelinka T, Petrá k O, Turková H, et al. High incidence of cardiovascular complications in pheochromocytoma. Horm Metab Res. 2012;44:379-384.
21. Stolk RF Bakx C Mulder J Timmers HJ Lenders JW Is the excess cardiovascular morbidity in pheochro mocytoma related to blood pressure or to catecholamines? J Clin Endocrinol Metab. 2013 98 1100-1106.
22. Plouin PF, Fitzgerald P, Rich T, et al. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res. 2012;44:390-399.
23. Brouwers FM, Eisenhofer G, Tao JJ, et al. High frequency ofSDHB germline mutations in patients with malignant catecholamine-producing paraga ngliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91:4505-4509.
24. Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in pati ents with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007;92:3822-3828.
25. Manger WM. The protean manifestations of pheochromocytoma. Horm Metab Res. 2009;41:658-663.
26. MelmedS, Polonsky KS, Reed Larsen P, KronenbergHM.Williams Textbook of Endocrinology. 12th ed. Philadelphia, PA: Elsevier; 2011.
27. Eisenhofer G, Keiser H, Friber g P, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab. 1998;83: 2175-2185.
28. Eisenhofer G, Huynh TT, Hiroi M, Pacak K. Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord. 2001; 2:297-311.
29. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004;56:331-349.
30. Manu P, Runge L A. Biochemical screening for pheochromocytoma. Superiority of urinary metanephrines measurements. Am J Epidemiol. 1984;120:788-790.
31. Peaston RT, Lai LC. Biochemical detection of phaeochromocytoma: should we still be measuring urinaryHMMA?J Clin Pathol. 1993;46:734-737.
32. Stewart MF, Reed P, Weinkove C, Moriarty KJ, Ralston AJ. Biochemical diagnosis of phaeochromocytoma: two instructive case reports. J Clin Pathol. 1993;46:280-282.
33. Gerlo EA, Sevens C. Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocytoma: diagnostic value in 19 cases. Clin Chem. 1994;40:250-256.
34. Shawar L, Svec F. Pheochromocytoma with elevated metanephrines as the only biochemical finding. J La State Med Soc. 1996; 148:535-538.
35. Hernandez FC, Sánchez M, Alvarez A, et al. A five-year report on experience in the detection of pheochromocytoma. Clin Biochem. 2000;33:649-655.
36. Gardet V, Gatta B, Simonnet G, et al. Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J Hypertens. 2001;19:1029-1035.
37. L.enders JW, Keiser HR, Goldstein DS, et al. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med. 1995; 123:101-109.
38. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med. 1999;340: 1872-1879.
39. Lenders JW, Pacak K, WaltherMM,et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287:1427-1434.
40. Raber W, Raffesberg W, Bischof M, et al. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochr omocytoma. Arch Intern Med. 2000;160:2957-2963.
41. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanep hrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003;88:553-558.
42. Unger N Pitt C Schmidt IL et al Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass Eur J Endocrinol. 2006 154 409-417.
43. Giovanella L, Squin N, Ghelfo A, Ceriani L. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan.QJ Nucl Med Mol Imaging. 2006;50:344-347.
44. Václaví k J, Stejskal D, Lacnák B, et al. Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens. 2007;25:1427-1431.
45. Gao YC, Lu HK, Luo QY, Chen LB, Ding Y, Zhu RS. Comparison of free plasma metanephrines enzyme immunoassay with (131)IMIBG scan in diagnosis of pheochromocytoma. Clin Exp Med. 2008;8:87-91.
46. Hickman PE, Leong M, Chang J, Wilson SR, McWhinney B. Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma. Pa thology. 2009;41:173-177.
47. Procopiou M, Finney H, Akker SA, et al. Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors. Eur J E ndocrinol. 2009;161: 131-140.
48. Grouzmann E, Drouard-Troalen L, Baudin E, et al. Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients wit h pheochromocytoma. Eur J Endocrinol. 2010;162:951-960.
49. Peaston RT, Graham KS, Chambers E, van der Molen JC, Ball S. Performance of plasma free metanephrines measured by liquid chromatography-t andem mass spectrometry in the diagnosis of pheochromocytoma. Clin Chim Acta. 2010;411:546-552.
50. Mullins F, O'Shea P, FitzGerald R, Tormey W. Enzyme-linked immunoassay for plasma-free metanephrine s in the biochemical diagnosis of phaeochromocytoma in adults is not ideal. Clin Chem Lab Med. 2012;50:105-110.
51. Sarathi V, Pandit R, Jagtap V, et al. Performance of plasma fractionated free metanephrines by enzyme immunoassay in the diagnosis of pheochromocytoma and paraganglioma. Endocr Pract. 2011;17:759-765.
52. Christensen TT, Frystyk J, Poulsen PL. Comparison of plasma metanephrin es measured by a commercial immunoassay and urinary catecholamines in the diagnosis of pheochromocytoma. Scand J Clin Lab Invest. 2011;71:695-700.
53. Unger N, Hinrichs J, Deutschbein T, et al. Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass. Exp Clin Endocrinol Diabetes. 2012; 120:494-500.
54. Perry CG, Sawka AM, Singh R, Thabane L, Bajnarek J, YoungWF Jr. The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf). 2 007;66:703-708.
55. Davidson DF. Phaeochromocytoma with normal urinary catecholamines: the potential value of urinary free metadrenalines. Ann Clin Biochem. 2002;39:557-566.
56. Boyle JG, Davidson DF, Perry CG, Connell JM. Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma. J Clin Endocrinol Metab 2007;92: 4602-4608.
57. Peitzsch M, Pelzel D, Gl öckner S, et al. Simultaneous liquid chromatography tandem mass spectrometric determination of urinary free metanephrines and ca techolamines, with comparisons of free and deconjugated metabolites. Clin Chim Acta. 2013;418:50-58.
58. Pillai D, Ross HA, Kratzsch J, et al. Proficiency test of plasma free and total metanephrines: report from a study group. Clin Chem Lab Med. 2009;47:786-790.
59. Pillai D, Callen S. Pilot quality assurance programme for plasma metanephrines. Ann Clin Biochem. 2010;47:137-142.
60. Eisenhofer G, Rundquist B, Aneman A, et al. Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab. 1995;80:3009-3017.
61. Eisenhofer G, Lenders J. Rapid circulatory clearances and half-lives of plasma free metanephrines. Clin Endocrinol (Oxf). 2012;77: 484-485.
62. Lagerstedt SA, O'Kane DJ, Singh RJ. Measurement of plasma free metanephrine and normetanephrine by liquid chromatographytandem mass spectrometry for diagnosis of pheochromocytoma. Clin Chem. 2004;50:603-611.
63. Heider EC Davis BG Frank EL Nonparametric determination of reference intervals for plasma metanephrine and normetanephrine Clin Chem. 2004 50 2381-2384.
64. Lenders JW, Willemsen JJ, Eisenhofer G, et al. Is supine rest necessary before blood sampling for plasma metanephrines? Clin Chem. 2007;53:352-354.
65. de Jong WH, Eisenhofer G, Post WJ, Muskiet FA, de Vries EG, Kema IP. Dietary infl uences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. J Clin Endocrinol Metab. 2009; 94:2841-2849.
66. Deutschbein T, Unger N, Jaeger A, Broecker-Pr euss M, Mann K, Petersenn S. Influence of various confounding variables and storage conditions on metanephrine and normetanephrine levels in plasma. Clin Endocrinol (Oxf). 2010;73:153-160.
67. de Jo ng WH, Graham KS, van der Molen JC, et al. Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. Clin Chem. 2007; 53:1684-1693.
68. Eis enhofer G, Lattke P, Herberg M, et al. Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Ann Clin Biochem. 2013;50:62-69.
69. Yu R, Wei M. False positive test results for pheochromocytoma from 2000 to 2008.ExpClin Endocrinol Diabetes. 2010;118:577-585.
70. A nas SS, Vasikaran SD. An audit of management of patients with borderline increased plasma-free metanephrines. Ann Clin Biochem. 2010;47:554-558.
71. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma:howto distinguish true-from falsepositive test results. J Clin Endocrinol Metab. 2003;88:2656-2666.
72. Dä rr R, Lenders JW, Stange K, et al. D iagnosis of pheochromocytoma and paraganglioma: the clonidine suppression test in patients with borderline elevations of plasma free normetanephrine [in German]. Dtsch Med Wochenschr. 2013;138:76-81.
73. Algecir as-Schimnich A, Preissner CM, Young WF Jr, Singh RJ, Grebe SK. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab. 2008;93:91-95.
74. Lenders JW, Eisenhofer G, Armando I, Keiser HR, Goldstein DS, Kopin IJ. Determination of metanephrines in plasma by liquid chromatography with elec trochemical detection. Clin Chem. 1993;39:97-103.
75. Ito T, Imai T, Kikumori T, et al. Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetane phrine result. Surg Today. 2006;36:961-965.
76. Bouhanick B, Fauvel J, Pont F. Biochemical misdiagnosis of pheochromocytoma in patients treated with sulfasalazine.JAMA.2010; 304:1898-1901.
77. Neary NM, King KS, Pacak K. Drugs and pheochromocytoma-don't be fooled by every elevated metanephrine. N Engl J Med. 2011;364:2268-2270.
78. Leow MK, Loh KC, Kiat Kwek T, Ng PY. Catecholamine and metanephrine excess in intracerebral haemorrhage: revisiting an obscure yet common "pseudophaeochromocytoma. " J Clin Pathol. 2007;60:583-584.
79. Shao Y, Chen R, Shen ZJ, et al. Preoperative-blockade for normotensive pheochromocytoma: is it necessary? J Hypertens. 2011; 29:2429-2432.
80. Timmers HJ, Pacak K, Huynh TT, et al. Biochemically s ilent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. J Clin Endocrinol Metab. 2008;93:4826-4832.
81. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma inSDHxmutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab. 2013; 98:E162-E173.
82. Ganguly A, Henry DP, Yune HY, et al. Diagnosis and localization of pheochromocytoma. Detection by measurement of urinary norepinephrine excretion during sleep, plasma norepinephrine concentration and computerized axial tomography (CT-scan). Am J Med. 1979;67:21-26.
83. Welch TJ, Sheedy PF 2nd, van Heerden JA, Sheps SG, Hattery RR, Stephens DH. Pheochromocytoma: value of computed tomography. Radiology. 1983;148:501-503.
84. van Gils AP, van der Mey AG, Hoogma RP, et al. Iodine-123- metaiodobenzylguanidine scintigraphy in patients with chemodectomas of the head and neck region. J Nucl Med. 1990;31:1147-1155.
85. Maurea S Cuocolo A Reynolds JC et al Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI J Nucl Med. 1993 34: 173-179.
86. Jalil ND, Pattou FN, Combemale F, et al. Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: a review of 282 cases. French Associatio n of Surgery (AFC), and The French Association of Endocrine Surgeons (AFCE). Eur J Surg. 1998;164:23-28.
87. Berglund AS, Hulthén UL, Manhem P, Thorsson O, Wollmer P, Törnquist C. Metaiod obenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of phaeochromocytomas. J Intern Med. 2001;249:247-251.
88. Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: detection with 18F DOPA whole body PET-initial results. Radiology. 2002;222:507-512.
89. Lumachi F, Tregnaghi A, Zucchetta P, et al. S ensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nucl Med Commun. 2006;27:583-587.
90. Luster M, Karges W, Zeich K, et al . Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging. 2010;37:484-493.
91. Ramsa y JA, Asa SL, van Nostrand AW, Hassaram ST, de Harven EP. Lipid degeneration in pheochromocytomas mimicking adrenal cortical tumors. Am J Surg Pathol. 1987;11:480-486.
92. Caoili EM, Korobkin M, Francis IR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology. 2002;222:629-633.
93. Blake MA, Krishnamoorthy SK, Boland GW, et al. Low-density pheochromocytoma on CT: a mimicker of adrenal adenoma. AJR Am J Roentgenol. 2003;181:1663-1668.
94. Motta-RamirezGA,RemerEM,Herts BR, Gill IS, HamrahianAH. Comparison of CT findings in sympt omatic and incidentally discovered pheochromocytomas. AJR Am J Roentgenol. 2005;185: 684-688.
95. Jacques AE, Sahdev A, Sandrasagara M, et al. Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. Eur Radiol. 2008;18:2885-2892.
96. Mukherjee JJ, Peppercorn PD, Reznek RH, et al. Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels. Radiology. 1997;202:227-231.
97. Baid SK, Lai EW, Wesley RA, et al. Brief communication: radiographic contrast infusion and catecholamine release in patients with pheochromocyto ma. Ann Intern Med. 2009;150:27-32.
98. Quint LE, Glazer GM, Francis IR, Shapiro B, Chenevert TL. Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and I-131 MIBG scintigraphy. Radiology. 1987;165: 89-93.
99. Maurea S, Cuocolo A, Reynolds JC, et al. Role of magnetic resonance in the study of benign and malignant pheochromocytom as. Quantitative analysis of the intensity of the resonance signal [in Italian]. Radiol Med Torino. 1993;85:803-808.
100. Maurea S, Cuocolo A, Reynolds JC, Neumann RD, Salvatore M. Diagnostic imag ing in patients with paragangliomas. Computed tomography, magnetic resonance andMIBGscintigraphy comparison. Q J Nucl Med. 1996;40:365-371.
101. Goldstein RE, O'Neill JA Jr, Holcomb GW 3rd, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999;229:755-764.
102. Sahdev A, Sohaib A, Monson JP, Grossman AB, Chew SL, Reznek RH. CT and MR imaging of unusual lo cations of extraadrenal paragangliomas (pheochromocytomas). Eur Radiol. 2005;15:85-92.
103. Shulkin BL, Shapiro B, Francis IR, Dorr R, Shen SW, Sisson JC. Primary extra-adrenal pheochromo cytoma: positive I-123 MIBG imaging with negative I-131 MIBG imaging. Clin Nucl Med. 1986; 11:851-854.
104. Furuta N, Kiyota H, Yoshigoe F, Hasegawa N, Ohishi Y. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol. 1999; 6:119-124.
105. Nakatani T, Hayama T, Uchida J, Nakamura K, Takemoto Y, Sugimura K. Diagnostic l ocalization of extra-adrenal pheochromocytoma: comparison of (123)I-MIBG imaging and (131)IMIBG imaging. Oncol Rep. 2002;9:1225-1227.
106. Lev I Kelekar G Waxman A Yu R Clinical use and utility of metaiodobenzylguanidine scintigraphy in pheochromocytoma diagnosis Endocr Pract. 2010 16 398-407.
107. Mozley PD, Kim CK, Mohsin J, et al. The efficacy of iodine-123-MIBG as a screening test for pheochromocytoma. J Nucl Med. 1994;35:1138-1144.
108. Bhatia KS, Ismail MM, Sahdev A, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extraadrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf). 2008;69:181-188.
109. Wiseman GA, Pacak K, O 'Dorisio MS, et al. Usefulness of 123IMIBG scintigraphy in the evaluation of patien ts with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med. 2009;50:1448-1454.
110. Fiebrich HB, Brouwers AH, Kerstens MN, et al. 6-[F-18]Fluoro L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causi ng catecholamine excess. J Clin Endocrinol Metab. 2009;94:3922-3930.
111. Milardovic R, Corssmit EP, Stokkel M. Value of 123I-MIBG scintigraphy in paraganglioma. Neuroendocrinology. 2010;91:94-100.
112. Ilias I, Chen CC, Carrasquillo JA, et al. Comparison of 6-18Ffluorodopamine PET wit h 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49:1613-1619.
113. Rufini V, Treglia G, Castaldi P, et al. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun. 2011;32:575-582.
114. van der Horst-Schrivers A N, Kerstens MN, Wolffenbuttel BH. Preoperative pharmacological management of phaeochromocytoma. Neth J Med. 2006;64:290-295.
115. Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR. 123Imeta- iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab 2010;95:2596-2606.
116. Fonte JS, Robles JF, Ch en CC, et al. False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer. 2012;19:83-93.
117. King KS, Chen CC, Alexopoulos DK, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18Ffluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D- glucose PET, 123I-metaiodobenzylguan idine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96:2779-2785.
118. Fottner C, Helisch A, Anlauf M, et al. 6-18F-fluoro-L- dihydroxyphenylalanine positron em ission tomography is superior to 123Imetaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95:2800-2810.
119. Timmers HJ, Chen CC, Carrasquillo JA, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission to mography. J Natl Cancer Inst. 2012;104:700-708.
120. Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques i n the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25: 2262-2269.
121. Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med. 2008;49:1232-1237.
122. Timmers HJ, Chen CC, Carrasquillo JA, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94:4757-4767.
123. Gabriel S, Blanchet EM, Sebag F, et al. Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions. Clin Endocrinol (Oxf). 2013;79:170-17 7.
124. Williams DT, Dann S, Wheeler MH. Phaeochromocytoma-views on current management. Eur J Surg Oncol. 2003;29:483-490.
125. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer P J, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992;13:513-521.
126. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology. 1999;212:35-41.
127. Ma mede M Carrasquillo JA Chen CC et al Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine-and [(123I)]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites Nucl Med Commun. 2006 27 31-36.
128. Mann GN, Link JM, Pham P, et al. [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol. 2006;13:187-197.
129. Takano A, Oriuchi N, Tsushima Y, et al. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy. Ann Nucl Med. 2008;22:395-401.
130. Taï eb D, Sebag F, Barlier A, et al. 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med. 2009;50:711-717.
131. Timmers HJ, Eisenhofer G, Ca rrasquillo JA, et al. Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol (Oxf). 2009; 71:11-17.
132. Taï eb D, Tessonnier L, Sebag F, et al. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf). 2008;69: 580-586.
133. Fathinul F, Nordin AJ, Zanariah H, et al. Localization and prediction of recurrent phaeochromocytoma/paraganglioma (PCC/PGL) using diagnostic 18[F]FDG-PET/CT. Cancer Imaging. 2011; 11: S114-S115.
134. Timmers HJ, Taieb D, Pacak K. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res. 2012;44:367-372.
135. Viskochil D, Buchberg AM, Xu G, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 1990;62:187-192.
136. Mulligan LM, Kwok J B, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458-460.
137. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317-1320.
138. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848-851.
139. Niemann S, Mü ller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26:268-270.
140. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunitSDHBcause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;69:49-54.
141. Lee S, Nakamura E, Yang H, et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005;8: 15 5-167.
142. Ladroue C, Carcenac R, Leporrier M, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med. 2008;359:2685-2692.
143. Schlisio S, Kenchappa RS, Vredeveld LC, et al. The kinesin KIF1B-acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008;22:884-893.
144. Hao HX, Khalimonch uk O, Schraders M, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science. 2009;325:1139-1142.
145. Gaal J, Burnichon N, Korpershoek E, et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2010;95:1274-1278.
146. Qin Y, Yao L, King EE, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 2010;42: 229-233.
147. Burnichon N, Briè re JJ, LibéR, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19:3011-3020.
148. Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011;43:663-667.
149. Zhuang Z Yang C Lorenzo F et al Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia N Engl J Med. 2012 367 922-930.
150. Astuti D, Ricketts CJ, Chowdhury R, et al. Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocr Relat Cancer. 2011;18:73-83.
151. Ladroue C, Hoogewijs D, Gad S, et al. Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. Haematologica. 2012;97:9-14.
152. Yao L, Barontini M, Niederle B, Jech M, Pfragner R, Dahia PL. Mutations of the metabolic genes IDH1, IDH2, and SDHAF2 are not major determinants of the pseudohypoxic phenotype o f sporadic pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 2010;95:1469-1472.
153. Lorenzo FR, Yang C, Ng Tang Fui M, et al.Anovel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med Berl. 2013;91:507-512.
154. Favier J, Buffet A, Gimenez-Roqueplo AP. HIF2A mutations in paraganglioma with polycythemia. N Engl J Med. 2012;367: 2161-2162.
155. Comino-Méndez I, de Cubas AA, Bernal C, et al. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet. 2013;22:2169-2176.
156. Pacak K, Jochmanova I, Pro danov T, et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol. 2013;31:1690-1698.
157. Buffet A, Venisse A, Nau V, et al.Adecade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. Horm Metab Res. 2012;44:359-366.
158. Mannelli M. Management and treatment of pheochromocytomas and paragangliomas. Ann NY Acad Sci. 2006;1073:405-416.
159. Benn DE, Gimenez-Roqueplo AP, Reilly JR, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2006;91:827-836.
160. Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER. Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat. 2007;28:143-149.
161. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma inSDHxmutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endoc rinol Metab. 2013; 98:E162-E173.
162. Mannelli M, Castellano M, Schiavi F, et al. Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab. 2009;94:1541-1547.
163. Cascó n A, Pita G, Burnichon N, et al. Genetics of pheochromocytoma and paraganglioma in Spanish patients. J Clin Endocrinol Metab. 2009;94:1701-1705.
164. Chew SL. Recent developments in the therapy of phaeochromocytoma. Expert Opin Investig Drugs. 2004;13:1579-1583.
165. Amar L , Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23: 8812-8818.
166. Burnichon N, Rohmer V, Amar L, et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab. 2009;94:2817-2827.
167. Jafri M, Whitworth J, Rattenberry E, et al. Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clin Endocrinol (Oxf). 2013;78:898-906.
168. Erlic Z, Rybicki L, Peczkowska M, et al. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res. 2009;15:6378-6385.
169. Ko rpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germlineSDHAgene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2011;96:E1472-E1476.
170. Lefebvre S Borson-Chazot F Boutry-Kryza N et al Screening of mutations in genes that predispose to hereditary paragangliomas and pheochromocytomas Horm Metab Res. 2012 44 334-338.
171. Yao L, Schiavi F, Cascon A, et al. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA. 2010;304:2611-2619.
172. Abermil N, Guill aud-Bataille M, Burnichon N, et al. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma. J Clin Endocrinol Metab. 2012;97:E805-E809.
173. Burnichon N, Casc ón A, Schiavi F, et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res. 2012;18:2828-2837.
174. Bayley JP, Kunst HP, Cascon A, et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 2010;11:366-372.
175. Jankovic RJ, Konstantinovic SM, Milic DJ, Mihailovic DS, Stosic BS. Can a patient be successfully prepared for pheochromocytoma surgery in three days? A case report. Minerva Anestesiol. 2007; 73:245-248.
176. Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst. 2008; 100:1260-1262.
177. Strataki s CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med. 2009;266:43-52.
178. Pasmant E, Sabbagh A, Masliah-Planchon J, et al. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1. J Natl Cance r Inst. 2011;103:1713-1722.
179. Hersh JH, American Academy of Pediatrics Committee on Genetics. Health supervision for children with neurofibromatosis. Pediatrics. 2008;121:633-642.
180. Bausch B, Koschker AC, Fassnacht M, et al. Comprehensive mutation scanning of NF1 in apparently sporadic cases of pheochromocytoma. J Clin Endocrinol Metab. 2006;91:3478-3481.
181. Burnichon N, Buffet A, Parfait B, et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet. 2012;21:5397-5405.
182. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 2003;63:5615-5621.
183. Grosse H, Schrö der D, Schober O, Hausen B, Dralle H. The importance of high-dose-receptor blockade for blood volume and hemodynamics in pheochromocytoma [in German]. Anaesthesist. 1990;39:313-318.
184. Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytomaparaganglioma syndromes. J Intern Med. 2009;266:19-42.
185. Ki ng KS, Prodanov T, Kantorovich V, et al. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol. 2011;29:4137-4142 .
186. van Hulsteijn LT, Dekkers OM, Hes FJ, Smit JW, Corssmit EP. Risk of malignant paraganglioma in SDHB-mutation and SDHDmutation carriers: a systematic review and meta-analysis. J Med Genet. 2012;49:768-776.
187. Eisenhofer G, Vocke CD, Elkahloun A, et al. Genetic screening for von Hippel-Lindau gene mutations in non-syndromic pheochromocytoma: low prevalence and false-positives or misdiagnosis indic ate a need for caution. Horm Metab Res. 2012;44:343-348.
188. Armstrong R, Sridhar M, Greenhalgh KL, et al. Phaeochromocytoma in children. Arch Dis Child. 2008;93:899-904.
189. Hammond PJ, Murphy D, Carachi R, Davidson DF, McIntosh D. Childhood phaeochromocytoma and paraganglioma: 100% incidence of genetic mutations and 100% survival. J Pediatr Surg. 2010;45:38 3-386.
190. Lahlou-Laforê t K, Consoli SM, Jeunemaitre X, Gimenez-Roqueplo AP. Presymptomatic genetic testing in minors at risk of paraganglioma and pheochromocytoma: our experience of oncogenetic multidisciplinary co nsultation. Horm Metab Res. 2012;44:354-358.
191. Cascón A Inglada-Pérez L Comino-Méndez I et al Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients Endocr Rel at Cancer. 2013 20L1-L6.
192. Neumann HP, Erlic Z, Boedeker CC, et al. Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnost ic process as fall-out. Cancer Res. 2009;69:3650-3656.
193. Ricketts CJ, Forman JR, Rattenberry E, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline muta tions in SDHB and SDHD. Hum Mutat. 2010;31: 41-51.
194. van Nederveen FH, Gaal J, Favier J, et al.Animmunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with ger mline SDHB,SDHC,orSDHDgene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009;10: 764-771.
195. Eisenhofer G, Lenders JW, Timmers H, et al. Measurements of plasma methoxytyra mine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2011;57:411-420.
196. Organisation for Economic Co-operation and Development. 2007 OECD guidelines for quality assurance in molecular genetic testing. http://www.oecd.org/science/biotech/38839788.pdf. Accessed January 3, 2014.
197. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-2406.
198. McGovern MM, E lles R, Ronchi E, Boone J, Lubin IM. Molecular genetic testing in the United States: comparison with international practice. Genet Test. 2008;12:187-193.
199. Berwouts S, Fanning K, Morri s MA, Barton DE, Dequeker E. Quality assurance practices in Europe: a survey of molecular genetic testing laboratories. Eur JHumGenet. 2012;20:1118-1126.
200. Plon SE, EcclesDM,Easton D, et al . Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29: 1282-1291.
201. Richards CS, Bale S, Belliss imo DB, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med. 2008;10:294-300.
202. Houdayer C, Caux-Moncoutier V, Krieger S, et al. Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies onBRCA1andBRCA2variants. Hum Mutat. 2012;33:1228-1238.
203. Lentschener C, Gaujoux S, Tesniere A, Dousset B. Point of controversy: perioperative care of patients undergoing pheochromocytoma removal-time for a reappraisal? Eur J Endocrinol. 2011; 165:365-373.
204. Wein garten TN, Cata JP, O'Hara JF, et al. Comparison of two preoperative medical management strategies for laparoscopic resection of pheochromocytoma. Urology. 2010;76:508.e6-e11.
205. Ross EJ, Prich ard BN, Kaufman L, Robertson AI, Harries BJ. Preoperative and operative management of patients with phaeochromocytoma. Br Med J. 1967;1:191-198.
206. Perry LB, Gould AB Jr. The anesthetic management of pheochromocytoma effect of preoperative adrenergic blocking drugs. Anesth Analg. 1972;51:36-40.
207. Young WF Jr. Pheochromocytoma: 1926-1993. Trends Endocrinol Metab. 1993;4:122-127.
208. Malchoff CD, MacGillivray D, Shichman S. Pheochromocytoma treatment. In: Mansoor GA, ed. Secondary Hypertension. Totowa, NJ: Humana Press; 2004:235-249.
209. Kinn ey MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth. 2002;16:359-369
210. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007;92:4069-4079.
211. Prys-Roberts C, Farndon JR. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg. 2002;26:1037-1042.
212. Hoffman BB. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, eds. Goodman & Gillman's The Pharmacological Basis of Therapeutics. Philadelphia; McGraw-Hill; 2001:215-268.
213. Kocak S Aydintug S Canakci N Alpha blockade in preoperative preparation of patients with pheochromocytomas Int Surg.2002 87 191-194.
214. Combemale F, Carnaille B, Tavernier B, et al. Exclusive use of calcium channel blockers and cardioselective-blockers in the preand per-operative management of pheochromocytomas. 70 cases [in French]. Ann Chir. 1998;52:341-345.
215. Ulchaker JC, Goldfarb DA, Bravo EL, Novick AC. Successful outcomes in pheochromocytoma surgery in the modern era. J Urol. 1999;161:764-767.
216. Lebuffe G, Dosseh ED, Tek G, et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia 2005;60: 439-444.
217. Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev. 1994;15:356-368
218. Briggs RS, Birtwell AJ, Pohl JE. Hypertensive response to labetalol in phaeochromocytoma. Lancet. 1978;1:1045-1046.
219. Perry RR, Keiser HR, Norton JA, et al. Surgical management of pheochromocytoma with the use of metyrosine. Ann Surg. 1990; 212:621-628.
220. Steinsapir J, Carr AA, Prisant LM, Bransome ED Jr. Metyrosine and pheochromocytoma. Arch Intern Med. 1997;157:901-906.
221. Wä ngberg B, Muth A, Khorram-Manesh A, et al. Malignant pheochromocytoma in a population-based study: survival and clinical results. Ann NY Acad Sci. 2006;1073:512-516.
222. Amar L, Fassnacht M, Gimenez-Roqueplo AP, et al. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res. 2012;44: 385-389.
223. Shen WT, Grogan R, Vriens M, Clark OH, Duh QY. One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy. Arch Surg. 2010;145:893-897.
224. Agarwal G, Sadacharan D , Aggarwal V, et al. Surgical manage-ment of organ-contained unilateral pheochromocytoma: comparative outcomes of laparoscopic and conventional open surgical procedures in a large single-institution series. Langenbecks Arch Surg. 2012;397:1109-1116.
225. Gagner M, Breton G, Pharand D, Pomp A. Is laparoscopic adrenalectomy indicated for pheochromocytomas? Surgery. 1996;120: 1076-1079.
226. Walz M K, Alesina PF, Wenger FA, et al. Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients. World J Surg. 2006;30:899-908.
227. Dickson PV, Alex GC, Grubbs EG, et al. Posterior retroperitoneoscopic adrenalectomy is a safe and effective alternative to transabdominal laparoscopic adrenalectomy for pheochromocytoma. Surgery. 2011;150:452-458.
228. Goers TA, Abdo M, Moley JF, Matthews BD, Quasebarth M, Brunt LM. Outcomes of resection of extra-adrenal pheochromocytomas/paragangliomas in the laparoscopic era: a comparison with adrenal pheochromocytoma. Surg Endosc. 2013;27:428-433
229. Scholten A, CiscoRM,VriensMR,et al. Pheochromocytoma crisis is not a surgical emergency. J Clin Endocrinol Metab. 2013;98: 581-591.
230. Li ML, Fitzgerald PA, Price DC, Norton JA. Iatrogenic pheochromocytomatosis: a previously unreported result of laparoscopic adrenalectomy. Surgery. 2001;130:1072-1077.
231. Brunaud L, Ayav A, Zarnegar R, et al. Prospective evaluation of 100 robotic-assisted unilateral adrenalectomies. Surgery. 2008; 144:995-1001.
232. Iihara M, Suzuki R, Kawamata A, et al. Adrenal-preserving laparoscopic surgery in selected patients with bilateral adrenal tumors. Surgery. 2003;134:1066-1072.
233. Kaye DR, Storey BB, Pacak K, Pinto PA, LinehanWM,Bratslavsky G. Partial adrenalectomy: underused first line therapy for small adrenal tumors. J Urol. 2010;184:18-25.
234. Benhammou JN Boris RS Pacak K Pinto PA LinehanWMBratslavsky G. Functional and oncologi c outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup J Urol. 2010 184 1855-1859.
235. Sanford TH, Storey BB, Lineh anWM,Rogers CA, Pinto PA, Bratslavsky G. Outcomes and timing for intervention of partial adrenalectomy in patients with a solitary adrenal remnant and history of bilateral phaeochromocytomas. BJU Int. 2011;107:571-575.
236. Volkin D, Yerram N, Ahmed F, et al. Partial adrenalectomy minimizes the need for long-term hormone replacement in pediatric patients with pheochromocytoma and von Hippel-Lindau syndrome. J Pediatr Surg. 2012;47:2077-2082.
237. Alesina PF, Hinrichs J, Meier B, Schmid KW, Neumann HP, Walz MK. Minimally invasive cortical-sparing surgery for bilateral pheochromocytomas. Langenbecks Arch Surg. 2012;397:233-238
238. Asari R, Scheuba C, Kaczirek K, Niederle B. Estimated risk of pheochromocytoma recurren ce after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch Surg. 2006;141:1199-1205.
239. Grubbs EG, Rich TA, Ng C, et al. Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J Am Coll Surg. 2013;216:280-289.
240. Brauckhoff M, Gimm O, Thanh PN, et al. Critical size of residual adrenal tissue and recovery from impaired early postoperati ve adrenocortical function after subtotal bilateral adrenalectomy. Surgery. 2003;134:1020-1027.
241. Eisenhofer G, Walther MM, Huynh TT, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab. 2001;86:1999-2008.
242. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292:943-951.
243. Timmers HJ, Kozupa A, Eisenhofer G, et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2007;92:779-786.
244. Eisenhofer G, Huynh TT, Elkahloun A, et al. Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma.AmJ Physiol Endocrinol Metab. 2008;295:E1223-E1233.
245. Timmers HJ, Gimenez-Roqueplo AP, Mannelli M, Pacak K. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2009;16:391-400.
246. Srirangalingam U, Khoo B, Walker L, et al. Contrasting clinical manifestations of SDHB andVHLassociated chromaffin tumours. Endocr Relat Cancer. 2009;16:515-525.
247. Welander J, Sö derkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011;18:R253-R276.
248. Eisenhofer G, Timmers HJ, Lenders JW, et al. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. J Clin Endocrinol Metab. 2011;96: 375-384.
249. Eisenhofer G, Pacak K, Huynh TT, et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer. 2011;18:97-111.
250. Opocher G, Schiavi F. Functional consequences of succinate dehydrogenase mutations. Endocr Pract. 2011;17(suppl 3):64-71.
251. Eisenhofer G, Tischler AS, de Krijger RR. Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratifi cation. Endocr Pathol. 2012;23:4-14.
252. Shah U, Giubellino A, Pacak K. Pheochromocytoma: implications in tumorigenesis and the actual management. Minerva Endocrinol. 2012;37:141-156.
253. Baez JC, Jagannathan JP, Krajewski K, et al. Pheochromocytoma and paraganglioma: imaging characteristics. Cancer Imaging. 2012;12:153-162.
254. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma inSDHxmutation carriers: a multicenter prospective study from the PGL.EVA investigators. J Clin Endocrinol Metab. 2013; 98:E162-E173.
255. Eisenhofer G Lenders JW Siegert G et al Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status Eur J Cancer. 2012 48 1739-1749.
256. Korevaar TI, Grossman AB. Pheochromocytomas and paragangliomas: assessment of malignant potential. Endocrine. 2011;40: 354-365.
257. Peitzsch M, Prejbisz A, Kroi M, et al. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-pro ducing metastatic phaeochromocytoma. Ann Clin Biochem. 2013;50:147-155.
258. Hoegerle S, Ghanem N, Altehoefer C, et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging. 2003;30:689-694.
259. Machens A, Brauckhoff M, Gimm O, Dralle H. Risk-oriented approach to hereditary adrenal pheochromocytoma. Ann NY Acad Sci. 2006;1073:417-428.
260. Gallagher SF, Wahi M, Haines KL, et al. Trends in adrenalectomy rates, indications, and physician volume: a statewide analysis of 1816 adrenalectomies. Surgery. 2007;142:1011-1021.
261. Park HS, Roman SA, Sosa JA. Outcomes from 3144 adrenalecto mies in the United States: which matters more, surgeon volume or specialty? Arch Surg. 2009;144:1060-1067.
262. Villar JM, Moreno P, Ortega J, et al. Results of adrenal surgery. Data of a Spanish National Survey. Langenbecks Arch Surg. 2010; 395:837-843.
263. Bergamini C, Martellucci J, Tozzi F, Valeri A. Complications in laparoscopic adrenalectomy: the value of experience. Surg Endosc. 2011;25:3845-3851.
264. Hernandez-Boussard T, McDonaldKM,Morton JM, Dalman RL, Bech FR. Determinants of adverse events in vascular surgery. J Am Coll Surg. 2012;214:788-797.
265. Wouters MW, Gooiker GA, van Sandick JW, Tollenaar RA. The volume-outcome relation in the surgical treat ment of esophageal cancer: a systematic review and meta-analysis. Cancer. 2012;118: 1754-1763.